A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplasti
Posted Date: May 15, 2019
- Investigator: Muhammad Riaz
- Type of Study: Drug
The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.
Criteria:
To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed
Keywords:
A091305, Thyroid Cancer, Cancer, Advanced Anaplastic , Head & Neck
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com